Navigation Links
Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer
Date:4/6/2009

A Drug That Improves Survival Would Earn a 50 Percent Patient Share in the U.S. and a 40 Percent Patient Share in Europe, According to a New Report from Decision Resources

WALTHAM, Mass., April 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in stage III prostate cancer. Clinical data and the opinions of interviewed thought leaders indicate that Sanofi-Aventis's Taxotere has advantages in this attribute over LHRH agonists, including Abbott's Lupron Depot, the sales-leading agent in the market.

The new report entitled Stage III Prostate Cancer: Oncologists Ready for New Type of Therapy finds that a drug that improves five-year disease-specific survival would earn a 50 percent patient share in stage III prostate cancer in the United States and a 40 percent patient share in Europe, according to surveyed U.S. and European oncologists.

In 2007, Decision Resources' proprietary clinical gold standard for stage III prostate cancer was Lupron Depot. Based on available data and expert opinion, Ferring Pharmaceuticals' degarelix will earn gold-standard status for stage III prostate cancer in 2012. Interviewed experts anticipate that degarelix, which has competitive advantages and has shown impressive Phase III clinical trial data, will be more effective than Lupron Depot.

"Interviewed experts are optimistic about the efficacy of some emerging agents in this market, most notably degarelix and Taxotere," said Decision Resources Analyst Natalia Reoutova. "In terms of improvements to survival, Taxotere, which has been approved for use in metastatic hormone-refractory prostate cancer, remains the most promising therapy for stage III prostate cancer and some interviewed physicians are already using it off-label."

About the Report

Stage III Prostate Cancer: Oncologists Ready for New Type of Therapy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                 Decision Resources, Inc.
    Christopher Comfort                Elizabeth Marshall
    781-296-2597                       781-296-2563
    ccomfort@dresources.com            emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
2. My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise
3. National Experts Offer Practical Tips for Parents Concerned about Autism
4. Covance Experts to Present Key Insights on Risk Management at Bio/Pharmaceutical Drug Safety Forum
5. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
6. Experts turn to Web to combat distressing skin disease
7. Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
8. Experts from Africa and Asia to Discuss Maternal Health in Live Online Chat
9. FDA Experts to Speak at RAPS Horizons Conference
10. Experts Revise Guidelines on Daily Aspirin for Heart
11. Experts Weigh in on Controversial Issue of Determining Value of Cancer Care at NCCN Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which is ... in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) ... website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, SEO ... already in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... ... 23, 2017 , ... The Center for Autism and Related ... Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The ... see films in an environment that accommodates their unique needs. , Launched in ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  As National ... In addition, the Company is helping people live ... its customized prescription savings programs in all 50 ... Prescription Assistance Program  and  California Prescription Assistance Program ... from Columbia University for nutritious eating ...
(Date:2/23/2017)... -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine ... develop and market advanced products and therapies for the ... Dental sectors of healthcare, today announced its record results ... 31, 2016. Full Year 2016 Highlights are: ... over full year 2015 revenue ...
(Date:2/23/2017)... Feb. 23, 2017 LG Innotek today announced that the ... applications. As its sterilization performance is 1.5 times higher than the ... ultraviolet rays in the range of 200 -- 280nm, allowing it to ... by destroying their DNA. LG Innotek,s product emits UV in the ... ...
Breaking Medicine Technology: